- Home
- DVS vs OCGN Comparison
DVS vs OCGN Comparison
Compare DVS & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DVS | OCGN |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 446.5M | 387.3M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | DVS | OCGN |
|---|---|---|
| Price | $3.24 | $2.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 1.2M | ★ 8.6M |
| Earning Date | 03-16-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4,139.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.48 | $0.57 |
| 52 Week High | $5.93 | $2.73 |
Technical Indicators
Market Signals| Indicator | DVS | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 25.98 | 61.94 |
| Support Level | N/A | $1.47 |
| Resistance Level | $3.96 | N/A |
| Average True Range (ATR) | 0.26 | 0.22 |
| MACD | -0.13 | 0.05 |
| Stochastic Oscillator | 0.82 | 60.44 |
Price Performance
Historical ComparisonAbout DVS Dolly Varden Silver Corporation
Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").